NorthStar Medical Radioisotopes announced today that it will provide Bayer with its environmentally preferred, non-carrier added (n.c.a.) therapeutic medical radioisotope, actinium‐225 (Ac‐225).

“We are very pleased to enter this Ac-225 supply agreement with Bayer, a global healthcare leader, and we look forward to working with them moving forward,” NorthStar Medical Radioisotopes CEO and President Frank Scholz said in a statement. “Our companies share a vision of developing and delivering innovative technology and compounds to drive research and ensure clinical availability or targeted radiopharmaceutical therapies for patients with cancer and other serious diseases.”

According to a release, the radioisotope will be used by Bayer for several of its radiopharmaceutical programs.

Ac‐225 is used in clinical studies investigating the use of radiopharmaceutical therapy.